Effectiveness of PEG-IFN alfa-2b + Ribavirin combination therapy in patients with chronic hepatitis C after partial splenic embolization(PSE) or splenectomy
Not Applicable
Recruiting
- Conditions
- Chronic Hepatitis C
- Registration Number
- JPRN-UMIN000001735
- Lead Sponsor
- Tokushima Municipal Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1)History of hypersensitivity to PEG-IFN alpha-2b or other interferons 2)History of hypersensitivity to biological products such as vaccine 3)Patients receiving shosaiko-to 4)Autoimmune hepatitis 5)Pregnant or lactating women and women who may be pregnant 6)History of hypersensitivity to ribavirin or other nucleoside analogs 7)Inadequately controlled cardiac disease 8)Hemoglobinopathy 9)Chronic renal failure or renal function disorder with creatinine clearance of 50 ml/min or less 10)With or with a history of severe psychosis such as severe depression, suicidal ideation or attempt, etc. 11)Serious hepatic function disorder 12)Judged by investigator not to be appropriate for inclusion in this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Sustained virological response(SVR)
- Secondary Outcome Measures
Name Time Method